|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:FA_Cup
|
|
gptkbp:administered_by
|
topical gel
|
|
gptkbp:approves
|
gptkb:2018
gptkb:2021
gptkb:FDA
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
Phase 1
Phase 2
Phase 3
improved quality of life
tolerability
well tolerated
reduced seizure frequency
reduction in seizure frequency
|
|
gptkbp:clinical_use
|
pediatric patients
adult patients
|
|
gptkbp:color
|
clear
|
|
gptkbp:contains
|
gptkb:cannabidiol
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to cannabidiol
|
|
gptkbp:developed_by
|
gptkb:Zynerba_Pharmaceuticals
|
|
gptkbp:dosage_form
|
gptkb:gel
|
|
gptkbp:duration
|
up to 12 hours
|
|
gptkbp:financial_support
|
gptkb:financial_assistance
gptkb:educational_resources
available
|
|
gptkbp:form
|
topical gel
|
|
gptkbp:formulation
|
transdermal
|
|
gptkbp:formulation_characteristics
|
non-invasive
easy to apply
controlled release
|
|
gptkbp:funding
|
gptkb:Zynerba_Pharmaceuticals
gptkb:NIH
pharmaceutical companies
private investors
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zygel
|
|
gptkbp:indication
|
gptkb:Dravet_syndrome
gptkb:Lennox-Gastaut_syndrome
|
|
gptkbp:ingredients
|
gptkb:cannabidiol
|
|
gptkbp:interacts_with
|
gptkb:beer
other CNS depressants
|
|
gptkbp:invention
|
gptkb:Zynerba_Pharmaceuticals
GW Pharmaceuticals
|
|
gptkbp:manufacturer
|
Epidiolex
|
|
gptkbp:marketed_as
|
gptkb:Zynerba_Pharmaceuticals
Epidiolex
cannabidiol gel
Zynerba's Zygel
|
|
gptkbp:mechanism_of_action
|
modulates cannabinoid receptors
|
|
gptkbp:packaging
|
gptkb:box
tube
|
|
gptkbp:patient_population
|
gptkb:children
adults
adolescents
|
|
gptkbp:premiered_on
|
1-2 hours
|
|
gptkbp:provides_guidance_on
|
recommended for refractory epilepsy
included in epilepsy treatment guidelines
|
|
gptkbp:publication
|
peer-reviewed journals
clinical studies published
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:release_region
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:reliability
|
gel-like
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research_areas
|
gptkb:epilepsy
neurology
cannabis-based therapies
|
|
gptkbp:research_focus
|
gptkb:epilepsy
neurological disorders
|
|
gptkbp:route_of_administration
|
topical
transdermal
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
twice daily
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
nausea
decreased appetite
diarrhea
drowsiness
irritation at application site
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:structure
|
C21 H30 O2
|
|
gptkbp:target_audience
|
patients with epilepsy
patients with Dravet syndrome
patients with Lennox-Gastaut syndrome
|
|
gptkbp:used_for
|
treatment of seizures
|
|
gptkbp:bfsParent
|
gptkb:Zynerba_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|